LLY.N Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

17.77B

+31.31%

7.182

+35%

17.36B

+36.39%

7.571

+126.68%

18.73B

+20.38%

8.018

+27.06%

Estimates Revision

The market is revising Upward the revenue expectations for Eli Lilly and Company (LLY) for FY2025, with the revenue forecasts being adjusted by 3.3% over the past three months. During the same period, the stock price has changed by 38.90%.

Revenue Estimates for FY2025

Revise Upward

+3.3%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+3.86%

In Past 3 Month

Stock Price

Go Up

+38.90%

In Past 3 Month

20 Analyst Rating

Wall Street analysts forecast LLY.N stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY.N is 1078 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

18 Buy

2 Hold

0 Sell

Strong Buy

Current: 1062.190

Low

800.00

Averages

1078

High

1300

Current: 1062.190

Low

800.00

Averages

1078

High

1300

Daiwa

Narumi Nakagiri

Neutral

Buy

upgrade

$1,230

2025-12-16

New

Reason

Daiwa

Narumi Nakagiri

Price Target

$1,230

2025-12-16

New

upgrade

Neutral

Buy

Reason

Daiwa analyst Narumi Nakagiri upgraded Eli Lilly to Buy from Neutral with a $1,230 price target.

Morgan Stanley

Terence Flynn

Overweight

maintain

$1,290

2025-12-11

New

Reason

Morgan Stanley

Terence Flynn

Price Target

$1,290

2025-12-11

New

maintain

Overweight

Reason

Morgan Stanley analyst Terence Flynn says Eli Lilly's retatrutide delivered what the firm views as "a competitive efficacy profile" in the first Phase 3 trial in obesity or overweight patients and osteoarthritis of the knee, but adds that the GI tolerability profile looks to be "somewhat worse" than tirzepatide. The firm, which points out that it recently lowered its retatrutide estimates and incorporated eloralinitide into its Lilly model as it sees eloralinitide being positioned further upstream in the future paradigm, expects "minimal movement" in Lilly shares on these first retatrutide data. The firm has an Overweight rating and $1,290 price target on Eli Lilly shares, which are up about 1% to $1,007 in pre-market trading.

HSBC

Hold

upgrade

$850

2025-12-10

Reason

HSBC

Price Target

$850

2025-12-10

upgrade

Hold

Reason

HSBC raised the firm's price target on Eli Lilly to $1,070 from $850 and keeps a Hold rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

BMO Capital

Outperform

maintain

2025-12-04

Reason

BMO Capital

Price Target

2025-12-04

maintain

Outperform

Reason

BMO Capital raised the firm's price target on Eli Lilly to $1,200 from $1,100 and keeps an Outperform rating on the shares. Following a string of positive readouts from Lilly's obesity pipeline Orforglipron and Eloralintide, the firm is assessing the potential scenarios for the upcoming TRIUMPH-4 readout for Retatrutide, the analyst tells investors in a research note, adding that BMO is anticipating 20%-23% weight loss and 50% or more in WOMAC pain score reduction as the base case. The firm adds that it believes diabetes will lead to durable and sustained growth for Eli Lilly as its pipeline strategy is beginning to bear fruit.

Guggenheim

Buy

maintain

2025-12-03

Reason

Guggenheim

Price Target

2025-12-03

maintain

Buy

Reason

Guggenheim raised the firm's price target on Eli Lilly (LLY) to $1,163 from $1,036 and keeps a Buy rating on the shares after updating the firm's Lilly and Novo Nordisk (NVO) models to reflect prescription trends and GLP-1 pricing updates and announcements. While noting that Lilly has "delivered another impressive year of stock performance in 2025," the firm "simply cannot argue with the company's superior overall execution capitalizing fully on the Pharma mega cycle of our lifetime," the analyst tells investors.

Morgan Stanley

NULL

Overweight

maintain

2025-11-24

Reason

Morgan Stanley

Price Target

2025-11-24

maintain

NULL

Overweight

Reason

Morgan Stanley raised the firm's price target on Eli Lilly to $1,290 from $1,171 and keeps an Overweight rating on the shares. The firm refreshed its model assumptions to incorporate recent developments in the GLP-1 space as well as insights from a proprietary primary care physician survey, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Eli Lilly and Co (LLY.N) is 33.95, compared to its 5-year average forward P/E of 40.21. For a more detailed relative valuation and DCF analysis to assess Eli Lilly and Co 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

40.21

Current PE

33.95

Overvalued PE

51.97

Undervalued PE

28.44

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

30.05

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

37.71

Undervalued EV/EBITDA

22.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

11.02

Current PS

0.00

Overvalued PS

13.89

Undervalued PS

8.16

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LLY.N News & Events

Events Timeline

No data

News

2.0

11:48 AMBenzinga

Novo Nordisk Slows Down as Eli Lilly Takes the Lead in Weight Loss Competition

6.5

09:00 AMNASDAQ.COM

What Does the Future Hold for Eli Lilly in a Decade?

8.0

12-15NASDAQ.COM

Significant Options Activity on Monday: ORCL, LLY, CRWD

People Also Watch

Frequently Asked Questions

What is Eli Lilly and Co (LLY.N) stock price today?

The current price of LLY.N is 1062.19 USD — it has increased 3.38 % in the last trading day.

What is Eli Lilly and Co (LLY.N)'s business?

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.

What is the price predicton of LLY.N Stock?

What is Eli Lilly and Co (LLY.N)'s revenue for the last quarter?

Eli Lilly and Co revenue for the last quarter amounts to 17.60B USD, increased 53.87 % YoY.

What is Eli Lilly and Co (LLY.N)'s earnings per share (EPS) for the last quarter?

Eli Lilly and Co. EPS for the last quarter amounts to 6.21 USD, increased 480.37 % YoY.

What changes have occurred in the market's expectations for Eli Lilly and Co (LLY.N)'s fundamentals?

How many employees does Eli Lilly and Co (LLY.N). have?

Eli Lilly and Co (LLY.N) has 47000 emplpoyees as of December 16 2025.

What is Eli Lilly and Co (LLY.N) market cap?

Today LLY.N has the market capitalization of 1,000B USD.